Curated News
By: NewsRamp Editorial Staff
November 09, 2026
Tonix Q3 Revenue Soars to $17.2M on TONMYA Strength
TLDR
- Tonix's TONMYA revenue hit $15 million, up 37% quarterly, with prescriptions rising 28% and coverage reaching 166 million lives.
- Tonix funds operations into early Q3 2027 with $163 million cash, advancing TNX-102 SL, TNX-4800, and TNX-1500 trials.
- Tonix's TONMYA offers fibromyalgia patients the first new treatment in over 15 years, with expanded access to 166 million lives.
- Tonix's TONMYA sales force grew to 150 reps, driving a 56% increase in refills and $15 million in quarterly revenue.
Impact - Why it Matters
Tonix’s strong revenue growth, driven by TONMYA’s rapid uptake, signals a potential turnaround for a company that has long been a speculative biotech play. For investors, the expanding patient access and sales force suggest that TONMYA could become a meaningful commercial franchise in fibromyalgia, a condition with high unmet need. The cash runway into early Q3 2027 reduces near-term financing risk, while the advancing pipeline—including programs in major depressive disorder, Lyme disease prevention, and kidney transplant rejection—offers multiple catalysts that could further derisk the investment thesis. For patients, TONMYA represents the first new fibromyalgia treatment in over 15 years, and its ongoing evaluation in other CNS conditions could eventually broaden therapeutic options. Overall, this news matters because it demonstrates Tonix’s ability to execute commercially while continuing to invest in innovative science, a combination that could create sustainable value for shareholders and improve outcomes for patients.
Summary
Tonix Pharmaceuticals (NASDAQ: TNXP) reported third-quarter 2026 financial results, highlighted by net product revenue of approximately $17.2 million, a more than fivefold increase from $3.3 million in the prior-year period. The growth was driven largely by TONMYA, the company’s flagship sublingual cyclobenzaprine product for fibromyalgia, which contributed $15 million in revenue—a 37% sequential increase. Total prescriptions rose 28% quarter over quarter to 16,375, with new prescriptions up 17% and refills climbing 56%. Tonix also expanded TONMYA coverage to approximately 166 million lives and increased its sales force to about 150 representatives. Despite the revenue surge, Tonix reported a net loss available to common stockholders of $53.3 million, or $2.89 per share, compared with a loss of $32 million, or $3.59 per share, a year earlier.
The company ended the quarter with approximately $163 million in cash and cash equivalents and expects its resources, together with about $1.5 million in subsequent equity financing proceeds, to fund operations into early third-quarter 2027. Tonix continues to advance its clinical pipeline, including the Phase 2 HORIZON study of TNX-102 SL for major depressive disorder, the planned Phase 2 TRAIL study of TNX-4800 for Lyme disease prevention, and an investigator-initiated Phase 2 study of TNX-1500 for kidney transplant rejection prevention. The latter two studies are expected to begin in the first quarter of 2027, with the TNX-4800 study pending final FDA agreement on its protocol. For full details, visit the complete press release.
Tonix is a fully integrated, commercial-stage biotechnology company focused on central nervous system and immunology treatments. TONMYA, approved as the first new fibromyalgia treatment in more than 15 years, is also being evaluated in Phase 2 trials for major depressive disorder and acute stress disorder. The company’s CNS portfolio includes acute migraine products Zembrace SymTouch and Tosymra, as well as TNX-2900 for Prader-Willi syndrome. Its immunology pipeline features TNX-4800 for Lyme disease prophylaxis and TNX-1500, a third-generation CD40 ligand inhibitor for preventing kidney transplant rejection. The news was distributed by TinyGems, a communications platform under the Dynamic Brand Portfolio @ IBN.
Source Statement
This curated news summary relied on content distributed by InvestorBrandNetwork (IBN). Read the original source here, Tonix Q3 Revenue Soars to $17.2M on TONMYA Strength
